PTCE Pharmacy Connect | Pharmacy Times

Епизоди

• Best Practices for Management of Hyperlipidemia: A Focus on Guidelines and Patient | PTCE Pharmacy Connect 31.03.2025 35мин

  Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Best Practices for Management of Hyperlipidemia: A Focus on Guidelines and Patient Adherence Educational Objectives Examine best practices for optimizing medication adherence and treatment initiation in hypercholesterolemia management Explain patient education and counseling for managing hypercholesteremia Faculty: Joseph Saseen, PharmD, BCPS, BCACP, CLS Professor and Associate Dean for Clinical Affairs University of Colorado Anschutz Medical Campus Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora, Colorado   Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Executive Director, Ambulatory Pharmacy Services Grady Health System Atlanta, Georgia Joseph Saseen, PharmD, BCPS, BCACP, CLS, has the following financial relationships with commercial interests to disclose: Other Support (Lipid Monitoring Committee): Amgen (VESALIUS and OCEAN(a))   Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA, has the following financial relationships with commercial interests to disclose: Grant/Research Support: Novartis Consultant: Novartis, Regeneron   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-9999-25-069-H01-P. The activity is available for CE credit through March 31, 2026.   This activity is jointly provided by the University of Connecticut School of Pharmacy–Storrs and Pharmacy Times Continuing Education™, and is supported by an educational grant from Novartis Pharmaceuticals Corporation.   Please follow the link below to access this activity on PTCE and claim CE credit: www.pharmacytimes.org/hyperlipidemiapodcast
• The Latest Updates and Pharmacist Perspectives on RET Inhibitors in Non-Small Cell Lung Cancer | PTCE Pharmacy Connect 30.10.2024 35мин

  Educational Objectives Review recent clinical updates of RET inhibitors and how they fit into the treatment paradigm for non‒small cell lung cancer Identify and manage adverse effects of RET inhibitors to ensure patient safety and improve adherence   Faculty Lauren Ledbetter, PharmD, BCOP Clinical Pharmacy Specialist, Thoracic Medical Oncology The James Cancer Hospital at The Ohio State University Columbus, Ohio   Moderator Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Clinical Pharmacy Manager University of Kansas Cancer Center Division of Hematologic Malignancies & Cellular Therapeutics   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-24-304-H01-P. The activity is available for CE credit through October 31, 2025.   This activity is supported by an educational grant from Rigel Pharmaceuticals, Inc.
• Alleviating Patient Burden in Acne: Utilizing Ceramides to Address Skin Barrier Dysfunction | PTCE Pharmacy Connect 29.04.2024 39мин

  Educational Objectives Review challenges that impact optimal treatment of skin barrier dysfunction in patients with acne who are seeking OTC care List strategies to individualize patient care and improve recommendations for patients with acne experiencing skin barrier dysfunction Faculty: Robin Laird Patient Advocate Los Angeles, California   Mary Barna Bridgeman, PharmD, BCPS, BCGP Clinical Professor Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey Piscataway, New Jersey   Internal Medicine Pharmacist Robert Wood Johnson University Hospital-New Brunswick New Brunswick, New Jersey Mary Barna Bridgeman, PharmD, BCPS, BCGP, has no relevant financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Liza Patel, PharmD, RPh; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose. An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.05 CEU) under the ACPE universal activity numbers 0290-0000-24-128-H01-P and 0290-0000-24-128-H01-T. The activity is available for CE credit through April 29, 2025. This activity is supported by an educational grant from CeraVe. 
• Challenges in Treatment of Desmoid Tumors and Managed Care Solutions | PTCE Pharmacy Connect 23.02.2024 26мин

    Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Title: Challenges in Treatment of Desmoid Tumors and Managed Care Solutions Educational Objectives • Recall the key characteristics of desmoid tumors (DT), including presentation, frequency, genetic mutations, development, and outlook for individual patients • Outline practical solutions to improve managed care-driven communication with health care providers and address the clinical and financial burden of unresectable, recurrent DT Moderator: Laura Bobolts, PharmD, BCOP Senior Vice President of Clinical Strategy and Growth OncoHealth Plantation, Florida   Faculty: Christy Harris, PharmD, BCOP, FHOPA     Clinical Pharmacy Specialist                                                                Dana-Farber Cancer Institute Associate Professor Massachusetts College of Pharmacy and Health Sciences Boston, Massachusetts   Christy Harris, PharmD, BCOP, FHOPA and Laura Bobolts, PharmD, BCOP have no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-23-421-H01-P. The activity is available for CE credit through February 28, 2024. This activity is supported by an educational grant from SpringWorks Therapeutics.  
• Examining Patient Burden in Atopic Dermatitis: Understanding Treatment Barriers and Optimal Use of OTC Skin Care Products, featuring a Caregiver Perspective | PTCE Pharmacy Connect 30.06.2023 30мин

  To claim CE credit for this activity, please follow this link: www.pharmacytimes.org/atopic-derm-podcast-630 Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Educational Objectives Review patient barriers that impact optimal treatment of patients with atopic dermatitis (AD) who are seeking OTC care List strategies to individualize patient care and improve recommendations for AD Moderator: Mary Bridgeman, PharmD, BCPS, BCGP Clinical Professor Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey Piscataway, New Jersey   Internal Medicine Clinical Pharmacist Robert Wood Johnson University Hospital New Brunswick, New Jersey   Faculty & Caregiver: Ashley Ellis, PharmD, MBA, CDECS ImPAcT Director & Assistant Professor The University of Tennessee Health Science Center Department of Clinical Pharmacy and Translation Science College of Pharmacy Memphis, Tennessee   Mary Bridgeman, PharmD, BCPS, BCGP has no financial relationships with commercial interests to disclose. Ashley Ellis, PharmD, MBA, CDECS, has the following financial relationships with commercial interests to disclose: Grant/Research Support: Researcher AHRQ “Tennessee Heart Health Network” funding in form of salary release dollars Consultant: Global Parents for Eczema Research, Continuing Education Alliance, McGraw Hill   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-23-268-H01-P and 0290-0000-23-268-H01-T. The activity is available for CE credit through June 30, 2024. This activity is supported by an educational grant from CeraVe and La Roche-Posay. Brought to you in partnership with the National Eczema Association.
• Continuing the Conversation: A Review of Targeted Therapies for Early-Stage Breast Cancer | PTCE Pharmacy Connect 31.05.2023 30мин

  Educational Objectives Outline the place in therapy for targeted therapies based on patient-specific factors and subtype of early-stage breast cancer Recognize methods to improve patient treatment selection while mitigating toxicities in patients with early-stage breast cancer Faculty: Allison R. Butts, PharmD, BCOP Pharmacist Manager, Oncology Breast Oncology Clinical Pharmacy Specialist Acute Care Pharmacy Services UK HealthCare- Markey Cancer Lexington, Kentucky   Director, PGY2 Oncology Residency Program UK HealthCare Lexington, Kentucky Allison R. Butts, PharmD, BCOP, has the following financial relationships with commercial interests to disclose: Consultant: AstraZeneca; BeyondSpring (one-time advisory boards) Moderator: Laura R. Bobolts, PharmD, BCOP SVP, Clinical Strategy and Growth OncoHealth Laura R. Bobolts, PharmD, BCOP, has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-23-239-H01-P. The activity is available for CE credit through May 31, 2024. This activity is supported by independent medical educational grants from AstraZeneca; Merck & Co., Inc.; Puma Biotechnology Inc., and Lilly.
• Treatment of Duchenne Muscular Dystrophy: Updates in Disease-Modifying Drugs | PTCE Pharmacy Connect 22.12.2022 46мин

  Educational Objectives Recall the pathophysiology and clinical manifestations of Duchenne muscular dystrophy (DMD), as well as the burden of DMD and its impact on patient quality of life List the latest updates for the safety and efficacy data of new and approved disease-modifying therapies in the treatment of DMD   Faculty: Amanda Hickman, PharmD, MPH, MSCS Central Support Pharmacist – Neuro/Psych/Sleep Trellis Rx Atlanta, Georgia   Moderator: Jessica L. Kerr, PharmD, CDCES Associate Dean – Office Professional and Student Affairs Professor/Clinical Pharmacist Southern Illinois University Edwardsville School of Pharmacy Edwardsville, Illinois   Amanda Hickman, PharmD, MPH, MSCS, and Jessica L. Kerr, PharmD, CDCES, have no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEU) under the ACPE universal activity number 0290-0000-22-613-H01-P. The activity is available for CE credit through December 22, 2023.   This activity is supported by an educational grant from Sarepta Therapeutics.
• Exploring the Emerging Treatment Landscape of Relapsed/Refractory Diffuse Large B-Cell | PTCE Pharmacy Connect 22.12.2022 35мин

  Educational Objective: Outline various challenges and uncertainties affecting the optimization of treatment with novel immunotherapeutic modalities for relapsed/refractory diffuse large B-cell lymphoma.   Faculty: Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist - Hematology University of Michigan Rogel Cancer Center Ann Arbor, Michigan   Moderator: Laura R. Bobolts, PharmD, BCOP SVP, Clinical Strategy and Growth OncoHealth Plantation, Florida   Victoria Nachar, PharmD, BCOP & Laura R. Bobolts, PharmD, BCOP, have no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-22-611-H01-P. The activity is available for CE credit through December 22, 2023.   This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc; Genmab; and AbbVie, Inc.
• Advances in the Treatment of Immune Thrombocytopenia: Strategies for Optimizing Clinical and Patient Outcomes | PTCE Pharmacy Connect 19.12.2022 49мин

  Educational Objectives Outline current guideline recommendations and strategies pharmacists can implement for the management of immune thrombocytopenia (ITP) Recall the efficacy and safety of emerging agents for the treatment of ITP   Moderator: Anthony J. Perissinotti, PharmD, BCOP To claim CE credit for this activity, please visit the link below: https://www.pharmacytimes.org/courses/advances-in-the-treatment-of-immune-thrombocytopenia-strategies-for-optimizing-clinical-and-patient-outcomes Hematology Clinical Pharmacist Specialist Clinical Team Leader Hematology/Oncology Adjunct Clinical Assistant Professor University of Michigan – Michigan Medicine Ann Arbor, Michigan   Faculty: Lisa Charneski, PharmD, BCPS Assistant Dean for Academic Affairs Philadelphia College of Pharmacy Associate Professor of Clinical Pharmacy Department of Pharmacy Practice Saint Joseph’s University Philadelphia, Pennsylvania Anthony J. Perissinotti, PharmD, BCOP has the following relevant financial relationships with commercial interests to disclose:Consultant: AbbVie, BeiGene, Janssen Lisa Charneski, PharmD, BCPS, has no relevant financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Karleen Melody, PharmD; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.1 CEU) under the ACPE universal activity number 0290-0000-22-608-H01-P. The activity is available for CE credit through December 19, 2023.   This activity is supported by an educational grant from Rigel Pharmaceuticals, Inc.
• Treatment Advancements in Atopic Dermatitis With JAK Inhibitors: Updates for Pharmacists | PTCE Pharmacy Connect 30.11.2022 31мин

  The educational objectives are: • Review the pathophysiology of atopic dermatitis (AD) as well as the efficacy and safety data for topical JAK inhibitors that are approved and in development • Discuss the role of pharmacists as a part of the care team for patients with AD as well as the key counseling points and monitoring parameters   Faculty: Dennis Williams Moderator: Jamie McConaha
• Continuing the Conversation: Exploring B-cell Maturation Antigen-Targeted Therapies and Managed Care Considerations for Patients With Multiple Myeloma | PTCE Pharmacy Connect 26.10.2022 34мин

  Educational Objectives Discuss the differing classes of B-cell maturation antigen-directed therapy for multiple myeloma Study the economic burden of multiple myeloma and cost-effective treatment strategies for B-cell maturation antigen-directed treatments Faculty: Joseph A. Kalis, PharmD, BCOP Ambulatory Oncology Pharmacist UCHealth Hematology/Oncology Colorado Springs, Colorado   Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA Director, Pharmacy Cancer Care Department of Pharmacy Mayo Clinic   Assistant Professor of Pharmacy Mayo Clinic College of Medicine and Sciences Rochester, Minnesota   Joseph A. Kalis, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:Speakers Bureau: Oncopeptides, GSK Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, has the following financial relationships with commercial interests to disclose:Grant/Research Support: AstraZeneza, Janssen Consultant: BeiGene Speakers Bureau: Pfizer   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-359-H01-P. The activity is available for CE credit through July 29, 2023.   This educational activity is supported by an educational grant from GlaxoSmithKline.
• Treatment Advancements in Anemia in Chronic Kidney Disease: Assessing HIF-PH Inhibitors | PTCE Pharmacy Connect 16.09.2022 40мин

  Introduction of moderator, faculty, and disclosures by Todd: ­We have an incredible discussion coming up with our moderator, Dr. Jessica Kerr, Professor and Clinical Pharmacy Specialist – Cardiometabolic at the Southern Illinois University Edwardsville School of Pharmacy in Illinois and Dr. Joanna Hudson, who is a tenured Professor in the Department of Clinical Pharmacy and Translational Science and the Department of Medicine (Division of Nephrology) at the University of Tennessee (UT) Health Science Center and a Clinical Pharmacist specializing in nephrology at Methodist Hospital in Memphis, TN. They will provide a brief overview of anemia in chronic kidney disease and highlight updates and advancements in the development of some of the emerging agents used.  If you haven't listened to the three other webinars in this learning series on anemia in chronic kidney disease, be sure to check them out at pharmacytimes.org. Outline updates and advancements in the development of HIF-PH inhibitors for anemia in chronic kidney disease.   Express the role of the pharmacist in managing anemia in CKD through early detection and coordination of care.    Guests:    Dr. Jessica Kerr PharmD Interim Associate Dean - Office of Professional and Student Affairs at Southern Illinois University Edwardsville   Dr. Joanna Hudson PharmD Professor at University of Tennessee Health Science Center Learn more about your ad choices. Visit megaphone.fm/adchoices
• Caring for Patients With Multiple Myeloma Through Pharmacist-Directed Supportive Care and Toxicity Management Strategies | PTCE Pharmacy Connect 14.09.2022 32мин

  Introduction of faculty and disclosures:  Dr. Kathryn Maples is a clinical pharmacy specialist in multiple myeloma at the Winship Cancer Institute with Emory Healthcare in Atlanta, Georgia. Dr. Maples has the following relevant financial relationships with commercial interests to disclose: consultant for GlaxoSmithKline, Janssen, Karyopharm, and Sanofi. Accreditation and support statement:  PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit. This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Learn more about your ad choices. Visit megaphone.fm/adchoices
• The Managed Care Implications of Cost, Disease Burden, and Quality of Life in Myelofibrosis | PTCE Pharmacy Connect 29.08.2022 29мин

  Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. The Managed Care Implications of Cost, Disease Burden, and Quality of Life in Myelofibrosis   Educational Objective: Recognize the quality-of-life impacts and cost of therapy challenges patients with myelofibrosis face and explore strategies available to better manage this diagnosis.       Melissa Pozotrigo, PharmD, BCOP Senior Clinical Pharmacist OncoHealth Atlanta, Georgia   Melissa Pozotrigo, PharmD, BCOP, has no financial relationships with commercial interests to disclose.     Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-397-H01-P. The activity is available for CE credit through August 29, 2023. This activity is supported by an educational grant from Incyte Corporation. Learn more about your ad choices. Visit megaphone.fm/adchoices
• Achieving Treatment Goals in Myelofibrosis with JAK Inhibitors and Emerging Therapies | PTCE Pharmacy Connect 29.08.2022 35мин

  Educational Objective: Outline the standard treatment options for myelofibrosis as well as review clinical data for Janus kinase inhibitors and emerging targeted therapies.     Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist, Hematology University of Michigan Rogel Cancer Center Clinical Assistant Professor University of Michigan College of Pharmacy Ann Arbor, Michigan     Victoria Nachar, PharmD, BCOP, has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-396-H01-P. The activity is available for CE credit through August 29, 2023. This activity is supported by an educational grant from Incyte Corporation. Learn more about your ad choices. Visit megaphone.fm/adchoices
• Setting the Scene in Myelofibrosis Treatment and Management | PTCE Pharmacy Connect 29.08.2022 25мин

  Educational Objective: Review the etiology and pathophysiology of myelofibrosis, including the World Health Organization classification and diagnostic criteria.     Victoria Nachar, PharmD, BCOP Clinical Pharmacist Specialist, Hematology University of Michigan Rogel Cancer Center Clinical Assistant Professor University of Michigan College of Pharmacy Ann Arbor, Michigan   Victoria Nachar, PharmD, BCOP, has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-381-H01-P. The activity is available for CE credit through August 29, 2023. This activity is supported by an educational grant from Incyte Corporation. Learn more about your ad choices. Visit megaphone.fm/adchoices
• Use of Novel Therapies in Endometrial Cancer: Update for Managed Care | PTCE Pharmacy Connect 29.07.2022 31мин

  Accreditation and support statement: ·   PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit. ·   This activity is supported by educational grant from GlaxoSmithKline. Objectives •   Review the guideline-recommended role of immune-based therapies in the management of endometrial cancer. •   Discuss access to care, cost of care and cost-effectiveness of Immune checkpoint inhibitors in the treatment of endometrial cancer.   Learn more about your ad choices. Visit megaphone.fm/adchoices
• HIV Preexposure Prophylaxis (PrEP): Exploring the Current and Emerging Landscape | PTCE Pharmacy Connect 29.07.2022 42мин

   Educational Objectives ·      Discuss currently available options for pre-exposure prophylaxis (PrEP) in the prevention of HIV. ·      Describe the role of pharmacists in improving PrEP uptake in the United States.      Faculty: Drew W. Cates, PharmD, AAHIVP, Educational Manager SynerGrx Chamblee, Georgia  Faculty, has the following financial relationships with commercial interests to disclose: Speaker's Bureau: Gilead   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.07 CEU) under the ACPE universal activity number 0290-0000-22-338-H02-P. The activity is available for CE credit through July 29, 2023. This activity is supported by an educational grant from ViiV. Learn more about your ad choices. Visit megaphone.fm/adchoices
• Multiple Myeloma: Pharmacists as Therapy Experts | PTCE Pharmacy Connect 29.07.2022 32мин

  Educational Objectives Objective 1: Describe a strategy to mitigate potential adverse effects of MM therapies by altering the route of administration, dosing schedule, and use of supportive care medications   Kathryn Maples, PharmD, BCOP Clinical Pharmacy Specialist, Multiple Myeloma Winship Cancer Institute, Emory Healthcare Atlanta, Georgia   Kathryn Maples, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:  Consultant: GlaxoSmithKline, Janssen, Karyopharm, Sanofi   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity numbers 0290-0000-22-315-H01-P and 0290-0000-22-315-H01-T. The activity is available for CE credit through July 11, 2023.   This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
• Examining the Treatment Landscape of Metastatic NSCLC Expressing the Targetable Mutations RET, MET, and KRAS | PTCE Pharmacy Connect 29.07.2022 32мин

  Educational Objectives • Review the targetable mutations RET, MET, and KRAS, including associated agents for the treatment of metastatic non-small cell lung cancer (NSCLC) • Discuss the ways a pharmacist may improve adherence, toxicity management, and outcomes for patients with metastatic NSCLC expressing RET, MET, and KRAS mutations   Josiah D. Land, PharmD, BCOP Clinical Pharmacy Specialist – Thoracic Medical Oncology Department of Pharmacy Memorial Sloan Kettering Cancer Center New York, New York   Josiah D. Land, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose: Consultant (advisory board): Bristol Myers Squibb   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number0290-0000-22-388-H01-P. The activity is available for CE credit through July 29, 2023.   This activity is supported by educational funding provided by Amgen. Learn more about your ad choices. Visit megaphone.fm/adchoices